New drug combo aims to keep mantle cell lymphoma in check
NCT ID NCT02896582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether adding the targeted drug obinutuzumab to standard chemotherapy (DHAP) and stem cell transplant could better control mantle cell lymphoma in 86 previously untreated patients. Participants received obinutuzumab during induction, before transplant, and as maintenance for up to 3 years. The main goal was to see if the cancer could be cleared at a molecular level in the bone marrow after initial treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Obinutuzumab (a targeted antibody drug) given with chemotherapy (DHAP, BEAM) and followed by stem cell transplant and maintenance therapy.
What this could lead to
If successful, this approach could improve long-term control of mantle cell lymphoma and reduce the chance of the cancer coming back.
What could go wrong
This is a small, early-phase trial (86 people) with no comparison group, so results may not apply broadly. The treatment involves strong chemotherapy and transplant, which carry serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP - Hopital Necker
Paris, 75743, France
-
CH Perpignan
Perpignan, 66046, France
-
CH d'Avignon
Avignon, 84902, France
-
CHD Vendée
La Roche-sur-Yon, 85925, France
-
CHRU Bretonneau
Tours, 37044, France
-
CHRU Lille - Hôpital Claude Huriez
Lille, 59037, France
-
CHU Limoges
Limoges, 87042, France
-
CHU Lyon Sud
Pierre-Bénite, 69130, France
-
CHU Montpellier
Montpellier, 34295, France
-
CHU Nantes
Nantes, 44093, France
-
CHU Pontchaillou
Rennes, 35033, France
-
CHU Robert Debré
Reims, 51092, France
-
CHU d'Amiens
Amiens, 80480, France
-
CHU d'Angers
Angers, 49000, France
-
CHU de Brabois
Vandœuvre-lès-Nancy, France
-
CHU de Caen
Caen, 14033, France
-
CHU de Clermont Ferrand
Clermont-Ferrand, 63000, France
-
CHU de Dijon - Hôpital le Bocage
Dijon, 21034, France
-
CHU de Grenoble
Grenoble, 38700, France
-
CHU de Haut Leveque
Pessac, 33604, France
-
CHU de Poitiers
Poitiers, 86021, France
-
CHU de Strasbourg
Strasbourg, 67091, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier Annecy-Genevois
Pringy, 74374, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Gustave Roussy Cancer Campus
Villejuif, 94805, France
-
Hopital Henri Mondor
Créteil, 94010, France
-
Hôpital Saint Louis
Paris, 75475, France
-
I.U.C.T Oncopole
Toulouse, 31100, France
-
Institut de Cancérologie de Loire
Saint-Priest-en-Jarez, 42271, France